In 1945, World War II ended. A new house cost about $4,600, a men’s shirt cost $2.50. Only 5,000 homes had a television set with only six channels. One hundred forty million people lived in the United States, and life expectancy was 65 years old.
Researchers at UM’s Diabetes Research Institute say the transplants of insulin-producing cells could move soon from study to regular practice......
....Ricordi and other researchers are excited about other parallel research:
• A new trial in conducting transplants that could eliminate the need of anti-rejection drugs by using the donor’s bone marrow cells to replace the recipient’s immune system.
• New materials to encapsulate and protect the islet transplants from the body’s immune system.
• New ways to deliver the anti-rejection drugs just to the cells that need it, instead of the entire body.
• Using cells from alternative sources, like targeting progenitor cells from a patient’s own pancreas, to regenerate as those special insulin-producing cells. That would eliminate the need for transplants and anti-rejection drugs.
Full text at link Abstract Vaccination is the administration of antigenic material to stimulate the immune system to develop adaptive immunity to a disease. As the most successful prophylactic in medical history, there is now an emerging interest as to whether vaccination can be applied in autoimmune and inflammatory conditions. These are diseases of failed immune regulation; vaccination in this context aims to exploit the power of antigenic material to stimulate immune homeostasis in the form of active, adaptive, regulatory immune responses. Type 1 diabetes is an autoimmune disease that could benefit from the therapeutic potential of vaccination. The major conditions necessary to make prophylaxis feasible are in place; the self antigens are known, the failure of existing immune regulation has been demonstrated, early studies of vaccine approaches have proved safe, and the preclinical prodrome of the disease can be easily detected by simple blood tests. Challenges for future implementation include finding the best mode of delivery and the best blend of adjunctive therapies that create the favorable conditions required for a vaccine to be effective.
Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of Internal Medicine. TUESDAY, Nov. 6 (HealthDay News) -- Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of Internal Medicine.
Christianne L. Roumie, M.D., M.P.H., from the Veterans Affairs Tennessee Valley Healthcare System in Nashville, and colleagues conducted a retrospective cohort study to compare outcomes for 253,690 veterans who initiated metformin (155,025) or sulfonylurea (98,665) therapy for diabetes. The composite outcome consisted of hospitalization for acute myocardial infarction or stroke, or death, adjusting for baseline demographic and medical characteristics.....
...Corresponding authors: Linda Haas, firstname.lastname@example.org, and Melinda Maryniuk, email@example.com. By the most recent estimates, 18.8 million people in the U.S. have been diagnosed with diabetes and an additional 7 million are believed to be living with undiagnosed diabetes. At the same time, 79 million people are estimated to have blood glucose levels in the range of prediabetes or categories of increased risk for diabetes. Thus, more than 100 million Americans are at risk for developing the devastating complications of diabetes (1).
I super appreciate the work of Firas H. El-Khatib and Ed Damiano et al!
...CONCLUSIONS A bihormonal bionic endocrine pancreas achieved excellent glycemic control with minimal hypoglycemia over the course of two days of continuous use despite high-carbohydrate meals and exercise. A trial testing a wearable version of the system under free-living conditions is justified.
Diabetes Health - Community: Diabetes Health. A report in the October 2012 issue of Diabetes Technology & Therapeutics says that airport full-body scans can cause malfunctions in insulin pumps or continuous glucose monitors.
In July 2012 I made my first trip to Vietnam as Education Manager for the International Diabetes Federation Life for a Child Program (IDF LFAC) and also as a support health professional for Caring and Living as Neighbours (CLAN).
Among the more than 25 million Americans who have diabetes is Jay Cutler, the Bears quarterback who was diagnosed with type 1 diabetes when he was with the Denver Broncos. Learning of the disease helped...
Objective This study was performed to compare in real-life conditions the serum profile of insulin lispro (IL) after a subcutaneous (SC) injection, separate and mixed with insulin glargine (IG), using a sensitive radioimmunoassay for the specific determination of serum IL, and to evaluate the 12-wk effect of the mixture on glycemic control in young individuals with type 1 diabetes.
Research design and methods The IL serum profiles were evaluated in 10 individuals with type 1 diabetes [age 21.9 ± 3.8 yr; diabetes duration 13.4 ± 4.9 yr; body mass index 25.1 ± 3.2 kg/m2; hemoglobin A1c (HbA1c) 8.3 ± 0.8%] during a mixed meal test (MMT) using IL and IG as separate (baseline) and mixed injection. The glycemic variability by continuous glucose monitoring system (CGMS) and the long-term diabetes control with HbA1c were also evaluated at baseline and after 12 wk mixing the two insulins.
Results The mixture of IL with IG decreased IL maximum serum concentration (CmaxIL) (29.4 ± 5.1 µU/mL vs. 13.7 ± 4.2 µU/mL; p = 0.03) without changing the time to reach the Cmax (TmaxIL), the IL area under the curve (AUCIL0-240), and the glucose dynamics during the MMT. The glucose variability and the HbA1c were equivalent to baseline after 12 wk mixing both insulins.
Conclusions These data suggest that mixing IL with IG immediately before the SC injection decreases IL serum peak concentration without affecting the glycemic profile after 12 wk in this group with type 1 diabetes mellitus.
Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market? Lisa S. Rotenstein, BA, Nina Ran, BA, Joseph P. Shivers, BA, Mark Yarchoan, MD and Kelly L. Close, MBA
Biosimilar insulins are likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulins have the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes. However, they will have to overcome numerous regulatory hurdles, meet a variety of commercial demands, and effectively confront competition from both established and next-generation branded insulin products before they can succeed on the global market.....
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.